Current Controversies, Recent Developments and Emerging Strategies in the Management of Breast Cancer: A Clinical Investigator Think TankQuality of life and choice of chemo
1:30 minutes.
TRANSCRIPTION:
DR LOVE: Chuck, what have you observed in terms of quality of life in patients on eribulin? DR VOGEL: Very little in the way of side effects. We have run into problems more with myelosuppression. These are all very heavily pretreated patients. Most of the patients who’ve received eribulin in our hands have been heavily pretreated, so we’ve run into more problems with myelosuppression. DR LOVE: What about nab paclitaxel? DR VOGEL: I prefer nab paclitaxel to paclitaxel because of all of the premedications that are necessary to use with paclitaxel. Unfortunately it’s a very expensive drug. So in the era when we had bevacizumab, I often would use nab paclitaxel with bevacizumab as opposed to paclitaxel. DR LOVE: What about ixabepilone? What’s your experience with that? DR VOGEL: With ixabepilone, we’ve found a lot of toxicity with it when given on a three-week schedule. We were among the leading accruers to one of the original ixabepilone studies and actually withdrew from the study because even our responding patients didn’t want to stay on it. |